Get the Stockscreener App
33.42
0.27%
0.09
After Hours:
33.42
Royalty Pharma Plc stock is traded at $33.42, with a volume of 4.55M.
It is up +0.27% in the last 24 hours and up +10.30% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$33.33
Open:
$33.29
24h Volume:
4.55M
Relative Volume:
1.20
Market Cap:
$14.48B
Revenue:
$2.27B
Net Income/Loss:
$1.15B
P/E Ratio:
13.11
EPS:
2.55
Net Cash Flow:
$2.80B
1W Performance:
+3.28%
1M Performance:
+10.30%
6M Performance:
+21.09%
1Y Performance:
+7.01%
1-Day Range:
$33.06
$33.67
1-Week Range:
$32.00
$33.69
52-Week Range:
$24.05
$33.69
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
33.42 | 14.48B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Bryn Mawr Capital Management LLC - MarketBeat
Baillie Gifford & Co. Sells 1,987,975 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week HighHere's What Happened - MarketBeat
Van ECK Associates Corp Increases Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Ex-Dividend Reminder: Royalty Pharma, Piedmont Office Realty Trust and Western Asset Diversified Income - Nasdaq
(RPRX) Trading Signals - Stock Traders Daily
Allspring Global Investments Holdings LLC Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) to Release Quarterly Earnings on Thursday - MarketBeat
Sumitomo Mitsui Trust Group Inc. Reduces Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
abrdn plc Sells 14,685 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat
Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition - MSN
Royalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook - Morningstar
Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts - MSN
Dechert advises Royalty Pharma on lupus drug funding - ICLG.com
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Lecap Asset Management Ltd. - MarketBeat
Royalty Pharma announces R&D funding collaboration with Biogen - TipRanks
Royalty Pharma: Delivering Growth With A Positive Story Ahead (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma Earnings: Solid Growth; Diverse Portfolio Supports Positive Long-Term Outlook - Morningstar
Royalty Pharma plc (RPRX) reports earnings - Quartz
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma - Benzinga
Royalty Pharma plc SEC 10-K Report - TradingView
Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D -February 12, 2025 at 08:32 am EST - Marketscreener.com
Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Royalty Pharma plc (RPRX): A Cheap Biotech Stock to Invest In Now - Yahoo Finance
Royalty Pharma plc (RPRX) Announces R&D Funding Collaboration With Biogen - StreetInsider.com
Massive $250M Deal: Royalty Pharma Backs Revolutionary Lupus Treatment in Late-Stage Trials - StockTitan
Royalty Pharma’s Optimistic Earnings Call Highlights Growth - TipRanks
Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... By GuruFocus - Investing.com Canada
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
Royalty Pharma PLC Reports Strong 2024 Financial Results - TipRanks
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings - MSN
Earnings call transcript: Royalty Pharma Q4 2024 misses EPS forecast By Investing.com - Investing.com Canada
Earnings call transcript: Royalty Pharma Q4 2024 misses EPS forecast - Investing.com India
Royalty Pharma earnings missed by $0.63, revenue fell short of estimates - Investing.com South Africa
Royalty Pharma (RPRX) Reports Q4 Revenue of $594 million - StreetInsider.com
Royalty Pharma reports Q4 portfolio receipts of $742M - TipRanks
Royalty Pharma Q4 Net Income, Revenue Decrease -February 11, 2025 at 07:41 am EST - Marketscreener.com
Royalty Pharma Reports Q4 and Full Year 2024 Results - TradingView
Royalty Pharma: Q4 Earnings Snapshot -February 11, 2025 at 07:31 am EST - Marketscreener.com
Earnings Flash (RPRX) Royalty Pharma Reports Q4 Revenue $594M, vs. FactSet Est of $687.1M - Marketscreener.com
Royalty Pharma Reports Strong Q4 and FY 2024 Financial Results with Expectations for Continued Growth in 2025 - Nasdaq
Royalty Pharma's Triple Win: 12% Revenue Jump, Massive Buyback, and Strategic Acquisition - StockTitan
Royalty Pharma Earnings: What To Look For From RPRX - Barchart
Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.05%
4.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):